75results about How to "Stable potency" patented technology

The persent invention relates to a sodium tanshinon IIA sulfonate glucose injection and its preparation method. Said injection contains (by wt%) 0.002-0.016% of sodium tanshinon IIA sulfonate, 5-25% of glucose, 0.05-0.2% of antioxidant and the rest is injection water. Said injection can obtain good therapeutic effect, and its preparation method is simple.

The invention provides an immunodetection kit. The immunodetection kit comprises 1) a conjugate carrier and 2) an immunochromatography test strip, wherein the conjugate carrier comprises a ligand, a marker and a solid-phase carrier, the ligand is used for generating specificity reaction with a to-be-measured analysis substance, the marker is used for signal detection, the ligand is connected withthe marker, and the solid-phase carrier is used for bearing the ligand and the marker, the conjugate carrier and the immunochromatography test strip are separately arranged. The kit can be stored andtransported under a room temperature and also has the characteristics of favorable accuracy, and the operation method is simple and rapid and is suitable for immediate detection. During measurement ofthe kit, a sample solution and the conjugate carrier are uniformly mixed and then are added into the immunochromatography test strip for detection, and a conjugate is more fully released. The kit isconvenient and rapid to fabricate, is low in manufacturing cost and can be compatible with existing assembly line equipment very well, and complicated process and high-cost equipment are not needed.

The invention discloses a virus (PRRSV) recombinant adenovirus rAd-GF35 of porcine reproduction and respiratory syndrome, which belongs to the technical field of high-tech biotechnology. Highly pathogenic PRRSV SY0608 separation strains of GP3 and GP5 protein genes and porcine colony sell stimulating factor (GMCSF) whole gene sequences are amplified, connected in series and cloned into pShuttle-CMV to be transformed into escherichia coli BJ5183 together with pAdEasy-1 so as to obtain recombinant plasmids; and HEK293A cells are transfected to obtain the recombinant adenovirus so as to successfully express PRRSV SY0608 strains GP3 and GP5 and a GMCSF protein. The recombinant virus can express the GMCSF correctly, and play a role of an adjuvant so as to improve the immune activity of the PRRSV GP3 and GP5 proteins and stimulate the immune protective reaction of an organism more effectively. The recombinant adenovirus vaccine has the safety of a subunit vaccine and the antigen proliferating ability of an attenuated vaccine, thereby having wide development and application prospect.

The invention relates to human immunoglobulin resisting the hand-foot-and-mouth disease and a preparation method of the human immunoglobulin. The hand-foot-and-mouth virus-neutralizing antibody titer is larger than or equal to 1:800. The preparation method comprises steps as follows: (1) efficient positive plasma with the hand-foot-and-mouth virus-neutralizing antibody titer larger than or equal to 1:80 is screened; (2) the screened efficient positive plasma is mixed; (3) the mixed plasma is separated with a low-temperature ethanol filter pressing method, immunoglobulin components II are purified and separated with an ion-exchange column chromatography method, and the immunoglobulin with the purity ranging from 98.5% to 100% is obtained through filtration, chromatography, ultrafiltration, preparation, incubation of inactivated viruses at low pH, virus removal through nanofilm filtration and subpackaging. By means of the preparation and production method, the hand-foot-and-mouth virus-neutralizing antibody titer, the purity and the recovery rate are high, enteroviruses can be treated in a targeted manner, and the human immunoglobulin is an effective medicine for treating an enterovirus infectious disease, is safe and reliable and has higher social benefits and economic benefits.

The invention belongs to the technical field of traditional Chinese medicines and discloses a traditional Chinese medicine for treating rhinitis and sinusitis and a preparation method of the traditional Chinese medicine. The traditional Chinese medicine for treating rhinitis and sinusitis comprises 100-300 parts by weight of centipeda minima, 100-300 parts by weight of cordate houttuynia, and 100-300 parts by weight of radix angelicae; a cotton swab is used to dip powder of the traditional Chinese medicine for treating rhinitis and sinusitis, the powder is fed into a nasal cavity, a patient takes a deep breath, the powder reaches a diseased region, the medicine is taken twice each day, and a course of treatment includes 14 days. The powder of the traditional Chinese medicine is used to treat rhinitis and sinusitis through an external inhalation method, is convenient to use, takes effects quickly, has good treatment effects, is non-toxic, and does not cause untoward effects; a patient with a mild symptom can also be treated by smelling the odor. Particularly, the traditional Chinese medicine has better treatment effects on purulent nasal mucus, nasal obstruction, airway obstruction and forehead ache caused by rhinitis and sinusitis, and takes effects quickly when being used to improve the symptoms of ventilation, purulent nasal mucus, forehead ache and the like.

A buccal lozenge for treating SARS, hepatitis B, hepatitis C and tumor is prepared from low-dosage recombinant human alpha-2b(IFN-alpha-2b) interferon and medical auxiliaries including mycose, maltose, sugar powder, staroh, gelatin and magnesium stearate. Its advantages are high curative effect, low poison, and low cost.

The invention provides a pigeon paramyxo virus type 1 PPMV-1 / BJ-C strain and application thereof. The attenuated strain PPMV-1 / BJ-C is constructed by mutating an F protein cleavage site of the attenuated strain PPMV-1 / BJ-C into a La Sota strain corresponding site on the basis of a pigeon plague virus virulent strain PPMV-1 / BJ. PPMV-1 / BJ-C has the advantages of good immunogenicity, good culture characteristics, stable titer and the like, the pigeon plague virus PPMV-1 / BJ-C strain is inoculated to 9-11-day-old SPF chick embryos through an allantoic cavity, allantoic fluid of infected chick embryos is harvested and inactivated with diethyleneimine, and then an aluminum hydroxide adjuvant is added to prepare a pigeon plague virus inactivated vaccine. The inactivated vaccine prepared from the PPMV-1 / BJ-C strain can generate a relatively high antibody, can prevent ND caused by pigeon plague virus, and the vaccine has the advantages of safety, quick response, lasting immune period and the like, and has wide application prospects.